SAFETY PROFILE OF PIRFENIDONE IN COVID19 RESPIRATORY DISTRESS SYNDROME

New kids on the interstitial lung disease block: COVID-19 and checkpoint inhibitors

Chair(s): Veronika Muller, Raquel Guillamat Prats

Session type: Poster session

Marta Hernandez Argudo

EVENTS HOME

Poster
Abstract

Previous presentation

Next presentation

Session content

Epidemiology and antifibrotic therapy of post-COVID-19 interstitial lung disease.

Oleh Yakovenko

Poster

Abstract

Neuroendocrine Cell Hyperplasia of Infancy (NEHI) during the Pandemic Era.

Vasilis Grammeniatis

Poster

Abstract

Late Breaking Abstract - Inhaled BTI615 regulates lung fibrotic-niche via confining TGF-?1 pathway in bleomycin rat-model

Qiu Jiang

Poster

Abstract

Late Breaking Abstract - Surfactant related chILD: a systematic review

Georgia-emmanouela Dendrinou

Poster

Abstract

The risk factors for developing post COVID-19 pulmonary fibrosis

Adriana Petronela Fildan

Poster

Abstract

Prevalence and Management of Post Covid fibrosis in tertiary care unit A single centre experience

Yussef Haider

Poster

Abstract

Effects of COVID-19 on telomere length and its relationship to pulmonary fibrosis

Alba Mulet Arabi

Poster

Abstract

Interstitial lung disease pattern in the upper lobes: etiologies, characteristics and prognosis

Houda Rouis

Poster

Abstract

Characterization of fibrosis-associated pathways in human lung tissue samples in COVID-19 and fibrotic lung diseases

Cathrin Kodde

Poster

Abstract

Long-COVID syndrome and interstitial lung disease following COVID-19

Dorottya Fesu

Poster

Abstract

SAFETY PROFILE OF PIRFENIDONE IN COVID19 RESPIRATORY DISTRESS SYNDROME

Marta Hernandez Argudo

Poster

Abstract

Cytoimmunological pattern of bronchoalveolar lavage in interstitial lung pathology related to post-COVID-syndrome: attempt to assess the predictive significance.

Piotr Kopinski

Poster

Abstract

Bronchoalveolar Lavage and post-COVID-19 interstitial lung disease

Sabrine Majdoub Fehri

Poster

Abstract

Enhanced liver fibrosis (ELF) test as a biomarker of pulmonary fibrosis (PF) secondary to COVID-19 pneumonia.

Alexa Gabriela Nunez Dubon

Poster

Abstract

Physical exercise in post-COVID patients

Jaume Bordas Martinez

Poster

Abstract

Comparative study assessing the pulmonary function sequalae in post Covid -19 patients during 1st and 2nd wave.

Rajesh Agrawal

Abstract

The inflammatory subtypes and vivo models of checkpoint inhibitor pneumonitis after immunotherapy

Jiangzhou Du

Poster

Abstract

Role of virtual multidisciplinary team meetings in the post-COVID era: a global survey to evaluate the ILD diagnostic pathway

Graham Lough

Poster

Abstract

Checkpoint inhibitor pneumonitis a tertiary centres experience

Su Latt Phyu

Poster

Abstract

Late Breaking Abstract - Characterising cough in hypersensitivity pneumonitis

Zhe Wu

Poster

Abstract

The ERS International Congress 2023, Milan

#{title}